About
Who We Are
Management Team
SpliSense Board of Directors
Technology
Our Platform
About Antisense Oligonucleotides (ASOs)
About Cystic Fibrosis
About Muco – Obstructive Lung (Pulmonary) Diseases
Pipeline
Intro
SPL84-23-1
SPL23-2
SPL16
Additional Opportunities
News
Presentations
Press Releases
Publications
Career
Contact Us
Menu
About
Who We Are
Management Team
SpliSense Board of Directors
Technology
Our Platform
About Antisense Oligonucleotides (ASOs)
About Cystic Fibrosis
About Muco – Obstructive Lung (Pulmonary) Diseases
Pipeline
Intro
SPL84-23-1
SPL23-2
SPL16
Additional Opportunities
News
Presentations
Press Releases
Publications
Career
Contact Us
Publications
Publication 1 - Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation
Publication 2 - Restoration of the cystic fibrosis transmembrane conductance regulator function by splicing modulation
Publication 3 - Introducing sense into nonsense in treatments of human genetic diseases
Publication 4 - The unfolded protein response affects readthrough of premature termination codons
Publication 5 - Take it personally: how personal we reach when we are so different from each other?
Publication 6 - The suppression of premature termination codons and the repair of splicing mutations in CFTR
Publication 7 - Muco-Obstructive Lung Diseases
Publication 8 - Antisense oligonucleotide splicing modulation as a novel Cystic Fibrosis therapeutic approach for the W1282X nonsense mutation
Scroll Up
Skip to content
Open toolbar
Accessibility Tools
Increase Text
Decrease Text
Grayscale
High Contrast
Negative Contrast
Light Background
Links Underline
Readable Font
Reset